Tabula Rasa HealthCare Inc (TRHC) Major Shareholder Sells $17,686,053.00 in Stock
Tabula Rasa HealthCare Inc (NASDAQ:TRHC) major shareholder Growth Fund 1Q Lp Originate sold 684,180 shares of the business’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $25.85, for a total value of $17,686,053.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Tabula Rasa HealthCare Inc (TRHC) traded down $0.01 during mid-day trading on Tuesday, hitting $28.59. The stock had a trading volume of 153,500 shares, compared to its average volume of 105,992. Tabula Rasa HealthCare Inc has a 1-year low of $11.59 and a 1-year high of $36.80. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.66 and a current ratio of 0.73.
Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Monday, November 6th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $33.27 million for the quarter, compared to analyst estimates of $31.76 million. Tabula Rasa HealthCare had a negative return on equity of 5.58% and a negative net margin of 2.27%. The business’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the company posted $0.06 EPS. equities research analysts predict that Tabula Rasa HealthCare Inc will post 0.05 EPS for the current fiscal year.
A number of brokerages have recently issued reports on TRHC. Zacks Investment Research downgraded Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. Piper Jaffray Companies restated an “overweight” rating and issued a $29.00 price target (up previously from $20.00) on shares of Tabula Rasa HealthCare in a report on Wednesday, September 20th. UBS upped their price target on Tabula Rasa HealthCare from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, August 30th. Wells Fargo & Company upped their price target on Tabula Rasa HealthCare from $21.00 to $27.00 and gave the stock a “market perform” rating in a report on Thursday, October 19th. Finally, ValuEngine upgraded Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Tabula Rasa HealthCare presently has an average rating of “Buy” and a consensus target price of $28.25.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.